DK1861100T3 - 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation - Google Patents

3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation

Info

Publication number
DK1861100T3
DK1861100T3 DK06765213T DK06765213T DK1861100T3 DK 1861100 T3 DK1861100 T3 DK 1861100T3 DK 06765213 T DK06765213 T DK 06765213T DK 06765213 T DK06765213 T DK 06765213T DK 1861100 T3 DK1861100 T3 DK 1861100T3
Authority
DK
Denmark
Prior art keywords
dihydrotetrabenazine
cis
treatment
disease
profiler
Prior art date
Application number
DK06765213T
Other languages
Danish (da)
English (en)
Inventor
Andrew John Duffield
Jean Elisabeth Yarrow
Original Assignee
Cambridge Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Lab Ireland Ltd filed Critical Cambridge Lab Ireland Ltd
Application granted granted Critical
Publication of DK1861100T3 publication Critical patent/DK1861100T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06765213T 2005-08-05 2006-08-04 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation DK1861100T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0516168.2A GB0516168D0 (en) 2005-08-05 2005-08-05 Pharmaceutical compounds
PCT/GB2006/002909 WO2007017643A1 (en) 2005-08-05 2006-08-04 3 , llB-CIS-DIHYDROTETRABENAZINE FOR THE TREATMENT OF A PROLIFERATIVE DISEASE OR AN INFLAMMATION

Publications (1)

Publication Number Publication Date
DK1861100T3 true DK1861100T3 (da) 2008-12-15

Family

ID=34984180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06765213T DK1861100T3 (da) 2005-08-05 2006-08-04 3,11B-cis-dihydrotetrabenazin til behandling af en profilerativ sygdom eller en inflammation

Country Status (23)

Country Link
US (1) US20090275605A1 (enExample)
EP (2) EP1964565A1 (enExample)
JP (1) JP2009503045A (enExample)
KR (1) KR20080033501A (enExample)
CN (1) CN101321528B (enExample)
AT (1) ATE412414T1 (enExample)
AU (1) AU2006277836B8 (enExample)
CA (1) CA2620952A1 (enExample)
CY (1) CY1108729T1 (enExample)
DE (1) DE602006003415D1 (enExample)
DK (1) DK1861100T3 (enExample)
ES (1) ES2317564T3 (enExample)
GB (1) GB0516168D0 (enExample)
HR (1) HRP20090017T3 (enExample)
MX (1) MX2008001546A (enExample)
NZ (1) NZ566010A (enExample)
PL (1) PL1861100T3 (enExample)
PT (1) PT1861100E (enExample)
RS (1) RS50720B (enExample)
RU (1) RU2409364C2 (enExample)
SI (1) SI1861100T1 (enExample)
WO (1) WO2007017643A1 (enExample)
ZA (2) ZA200801171B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB0721669D0 (en) * 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
CA2936823A1 (en) 2014-01-27 2015-07-30 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
WO2017164407A1 (ja) * 2016-03-25 2017-09-28 国立大学法人東北大学 免疫チェックポイント阻害作用を有するインドールアルカロイド型化合物
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3053845A (en) * 1962-09-11 Benzofykedocolines
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2843591A (en) 1958-07-15 Method for preparing same
US3132147A (en) * 1964-05-05
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3123609A (en) * 1964-03-03 Benzo
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US3009918A (en) * 1961-11-21 Chz ch
US3159638A (en) * 1964-12-01 Xcha-chj
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
US3634431A (en) * 1969-12-22 1972-01-11 Miles Lab Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
EP0211595B1 (en) * 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
CA2673334C (en) * 2003-06-16 2013-11-12 Andrx Pharmaceuticals, Llc Oral extended-release composition
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
AU2006277836B8 (en) 2011-12-08
PL1861100T3 (pl) 2009-06-30
CY1108729T1 (el) 2014-04-09
EP1964565A1 (en) 2008-09-03
ES2317564T3 (es) 2009-04-16
EP1861100A1 (en) 2007-12-05
MX2008001546A (es) 2008-04-04
PT1861100E (pt) 2008-12-26
JP2009503045A (ja) 2009-01-29
ZA200801170B (en) 2009-12-30
GB0516168D0 (en) 2005-09-14
HRP20090017T3 (hr) 2009-03-31
DE602006003415D1 (de) 2008-12-11
CN101321528B (zh) 2011-05-25
AU2006277836B2 (en) 2011-11-10
CN101321528A (zh) 2008-12-10
NZ566010A (en) 2010-05-28
RS50720B (sr) 2010-08-31
RU2008108516A (ru) 2009-09-10
AU2006277836A1 (en) 2007-02-15
EP1861100B1 (en) 2008-10-29
US20090275605A1 (en) 2009-11-05
KR20080033501A (ko) 2008-04-16
SI1861100T1 (sl) 2009-04-30
RU2409364C2 (ru) 2011-01-20
ZA200801171B (en) 2009-08-26
HK1111084A1 (en) 2008-08-01
CA2620952A1 (en) 2007-02-15
ATE412414T1 (de) 2008-11-15
WO2007017643A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
ECSP067095A (es) Compuestos y metodos para el tratamiento de dislipidemia
CY1108729T1 (el) 3,11b-cis-διυδpotetpabenazinh για την θεραπευτικη αντιμετωπιση μιας πολλαπλασιαστικης νοσου ή φλεγμονωδους παθησης
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CU20080044A7 (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno.
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο
PT2056814E (pt) Compostos de 2,5-di-hidroxibenzeno para o tratamento da psoríase
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007002479A1 (es) Compuestos derivados de pirazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos tromboembolicos.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
DK1801108T3 (da) Morpholinforbindelser til behandling af inflammationer.
CY1110027T1 (el) Συνδυασμος ενωσεων πυριμιδυλαμινοβενζαμιδης και ιματινιβης για τη θεραπεια ή την προληψη των νεοπλασματικων ασθενειων
CL2008000949A1 (es) Compuestos derivados de 2,3-benzodiazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos psicoticos.
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.